X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA SUN PHARMA SHASUN PHARMA/
SUN PHARMA
 
P/E (TTM) x 123.9 15.2 814.0% View Chart
P/BV x 8.5 3.6 238.4% View Chart
Dividend Yield % 0.2 0.2 108.9%  

Financials

 SHASUN PHARMA   SUN PHARMA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
SUN PHARMA
Mar-16
SHASUN PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs941,201 7.8%   
Low Rs46706 6.5%   
Sales per share (Unadj.) Rs214.2117.5 182.3%  
Earnings per share (Unadj.) Rs5.319.6 27.2%  
Cash flow per share (Unadj.) Rs15.823.8 66.4%  
Dividends per share (Unadj.) Rs1.001.00 100.0%  
Dividend yield (eoy) %1.40.1 1,364.2%  
Book value per share (Unadj.) Rs53.3130.5 40.9%  
Shares outstanding (eoy) m56.622,406.60 2.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.38.1 4.0%   
Avg P/E ratio x13.148.7 26.9%  
P/CF ratio (eoy) x4.440.1 11.0%  
Price / Book Value ratio x1.37.3 17.9%  
Dividend payout %18.75.1 367.2%   
Avg Mkt Cap Rs m3,9582,294,813 0.2%   
No. of employees `000NA14.7 0.0%   
Total wages/salary Rs m2,16447,971 4.5%   
Avg. sales/employee Rs ThNM19,169.8-  
Avg. wages/employee Rs ThNM3,253.0-  
Avg. net profit/employee Rs ThNM3,197.9-  
INCOME DATA
Net Sales Rs m12,127282,697 4.3%  
Other income Rs m2296,170 3.7%   
Total revenues Rs m12,356288,867 4.3%   
Gross profit Rs m1,00983,239 1.2%  
Depreciation Rs m59410,135 5.9%   
Interest Rs m4154,769 8.7%   
Profit before tax Rs m23074,505 0.3%   
Minority Interest Rs m0-11,126 0.0%   
Prior Period Items Rs m0-19 1.6%   
Extraordinary Inc (Exp) Rs m0-6,852 0.0%   
Tax Rs m-739,349 -0.8%   
Profit after tax Rs m30247,159 0.6%  
Gross profit margin %8.329.4 28.3%  
Effective tax rate %-31.712.5 -252.3%   
Net profit margin %2.516.7 14.9%  
BALANCE SHEET DATA
Current assets Rs m6,884308,646 2.2%   
Current liabilities Rs m8,456132,477 6.4%   
Net working cap to sales %-13.062.3 -20.8%  
Current ratio x0.82.3 34.9%  
Inventory Days Days6283 74.3%  
Debtors Days Days10888 122.6%  
Net fixed assets Rs m4,970133,606 3.7%   
Share capital Rs m1132,407 4.7%   
"Free" reserves Rs m2,875266,909 1.1%   
Net worth Rs m3,020314,042 1.0%   
Long term debt Rs m1,81731,167 5.8%   
Total assets Rs m13,347542,196 2.5%  
Interest coverage x1.616.6 9.3%   
Debt to equity ratio x0.60.1 606.3%  
Sales to assets ratio x0.90.5 174.3%   
Return on assets %5.49.6 56.1%  
Return on equity %10.015.0 66.6%  
Return on capital %13.317.8 75.1%  
Exports to sales %46.414.0 331.2%   
Imports to sales %14.23.1 453.4%   
Exports (fob) Rs m5,62239,572 14.2%   
Imports (cif) Rs m1,7288,882 19.5%   
Fx inflow Rs m5,84342,171 13.9%   
Fx outflow Rs m2,17321,583 10.1%   
Net fx Rs m3,66920,588 17.8%   
CASH FLOW
From Operations Rs m39867,694 0.6%  
From Investments Rs m-1,635-44,549 3.7%  
From Financial Activity Rs m1,309-19,243 -6.8%  
Net Cashflow Rs m713,902 1.8%  

Share Holding

Indian Promoters % 39.2 63.7 61.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 5.1 70.2%  
FIIs % 17.6 23.0 76.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 8.3 477.1%  
Shareholders   20,750 133,026 15.6%  
Pledged promoter(s) holding % 12.3 0.5 2,318.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   ORCHID PHARMA LTD  WYETH LTD  ABBOTT INDIA  FULFORD INDIA  DR. REDDYS LAB  

Compare SHASUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS